All In Biotech

Drug Trial Radar · NCT07214311

Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

RETAIN: A Phase 2/3 Randomized, Placebo-Controlled Study to Evaluate the Efficacy of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Total Knee Arthroplasty (TKA)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Feb 3, 2026

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
PeptilogicsIndustry
Sponsor type
Industry
First posted
Oct 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement, Antibiotics, and Implant Retention) surgical procedure to treat a Prosthetic Joint Infection (PJI). The study will also assess the safety of PLG0206 when used as an irrigation solution during the DAIR procedure. Participants will receive either PLG0206 or a placebo (an inactive substance that looks like the investigational drug), in addition to standard of care treatments. All participants will be monitored for approximately one year following their DAIR procedure.

Conditions

  • Prosthetic-joint Infection

Interventions

  • PLG0206Drug

    PLG0206 Solution

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction in Treatment Failure Post DAIRTime frame: From treatment through 12 months

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Pensacola, Florida · Recruiting

  • Clinical Trial Site

    Sarasota, Florida · Recruiting

  • Clinical Trial Site

    Tamarac, Florida · Recruiting

  • Clinical Trial Site

    Shreveport, Louisiana · Recruiting

  • Clinical Trial Site

    Baltimore, Maryland · Withdrawn

  • Clinical Trial Site

    Boston, Massachusetts · Recruiting

  • Clinical Trial Site

    New York, New York · Withdrawn

  • Clinical Trial Site

    Leland, North Carolina · Recruiting

  • Clinical Trial Site

    Cincinnati, Ohio · Recruiting

  • Clinical Trial Site

    Cleveland, Ohio · Recruiting

  • Clinical Trial Site

    Columbus, Ohio · Recruiting

  • Clinical Trial Site

    Pittsburgh, Pennsylvania · Recruiting

  • Clinical Trial Site

    Dallas, Texas · Recruiting

  • Clinical Trial Site

    Edinburg, Texas · Recruiting

  • Clinical Trial Site

    Katy, Texas · Recruiting

  • Clinical Trial Site

    Salt Lake City, Utah · Recruiting

  • Clinical Trial Site

    Morgantown, West Virginia · Recruiting

  • Clinical Trial Site

    Cambridge, Cambridgeshire, United Kingdom · Recruiting

  • Clinical Trial Site

    Edinburgh, Lothian, United Kingdom · Recruiting

  • Clinical Trial Site

    Norwich, Norfolk, United Kingdom · Recruiting

  • Clinical Trial Site

    Sheffield, South Yorkshire, United Kingdom · Recruiting

  • Clinical Trial Site

    Clydebank, Strathclyde, United Kingdom · Recruiting

  • Clinical Trial Site

    Coventry, West Midlands, United Kingdom · Recruiting

  • Clinical Trial Site

    Leeds, West Yorkshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.